Canaccord maintains Buy on Tandem stock, target at $63

Tuesday, Canaccord Genuity confirmed its Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) shares with a stable price target of $63.00. According to InvestingPro data, analyst targets for TNDM range from $18 to $75, with the stock currently trading at $34.02. The company maintains a moderate debt level and strong liquidity, with a current ratio of 2.9x indicating solid short-term financial stability. This endorsement follows Tandem’s recent announcement of FDA clearance for its Control-IQ+ automated insulin delivery (AID) algorithm for Type 2 diabetes. The firm acknowledged Tandem’s delay compared to Insulet (NASDAQ:PODD) in acquiring the Type 2 indication but highlighted that the race now primarily involves Tandem and Insulet, as Medtronic (NYSE:MDT) is not anticipated to receive FDA clearance until late 2025 or 2026.

Canaccord Genuity perceives this development as a significant catalyst for Tandem and the pump industry over multiple years, given the substantial potential increase in revenue. The firm’s analysis suggests that, focusing solely on the Type 2 diabetes Intensive Insulin Therapy (IIT) patient population in the United States, which is conservatively estimated at 2 million individuals, each 1% of market penetration could yield approximately $103 million in first-year revenues for Tandem. This potential growth is particularly significant given the company’s current annual revenue of $854 million and recent revenue growth of 10.75%. InvestingPro analysis reveals 7 additional key insights about Tandem’s financial position and growth prospects. This figure is based on the sales of pumps and disposables to 20,000 patients, with an additional $20 million in recurring revenues from disposables annually.

The Control-IQ+ algorithm is designed to automate insulin delivery, adapting to the needs of individuals with Type 2 diabetes—a condition that affects a significant portion of the population and requires precise management. Tandem’s technology aims to simplify this process and improve patients’ quality of life.

The FDA clearance marks a key milestone for Tandem, allowing the company to expand its market presence and provide an innovative solution to a broader range of patients. With the anticipated growth in market share and the associated revenue increase, Tandem is positioned to strengthen its foothold in the diabetes care industry.

Canaccord’s reiteration of the Buy rating and price target is based on these factors, suggesting confidence in Tandem’s strategy and potential for growth following the FDA’s approval of its AID algorithm for Type 2 diabetes.

In other recent news, Tandem Diabetes Care has received FDA clearance for its Control-IQ+ technology, allowing its use in adults with type 2 diabetes. This development extends the company’s automated insulin delivery solutions, previously available for type 1 diabetes, to a broader audience. The technology, which enhances Tandem’s existing Control-IQ algorithm, is expected to be available in the U.S. by March 2025. Analysts from Canaccord Genuity have noted this clearance as a significant catalyst for Tandem and the insulin pump industry, citing substantial revenue potential. Meanwhile, TD Cowen has adjusted its outlook on Tandem Diabetes, reducing the price target from $45 to $40 but maintaining a Buy rating, emphasizing new growth opportunities in 2025. Morgan Stanley (NYSE:MS) upgraded Tandem Diabetes to Overweight with a price target of $45, highlighting the company’s strong financial performance and the successful rollout of its MOBI product. The firm also pointed out the potential market expansion with the type 2 diabetes product launch, which could significantly increase the company’s market reach. Tandem Diabetes plans to finalize its FDA filing for type 2 diabetes by the end of the fourth quarter, anticipating clearance in early 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.